Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands
Ketevan Gendzekhadze(City Of Hope National Medical Center), Peter Parham(Stanford University), Thorsten Graef(Beth Israel Deaconess Medical Center), Z. Layrisse(Instituto Venezolano de Investigaciones Científicas), Achim K. Moesta(Rapt Therapeutics (United States)), Paul J. Norman(University of Colorado Denver), Laurent Abi-Rached(Stanford University)
Cited by 118
Related Papers
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans
|Nature Genetics|2007|222
NKp46 and NKG2D Recognition of Infected Dendritic Cells Is Necessary for NK Cell Activation in the Human Response to Influenza Infection
|The Journal of Immunology|2007|198